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Abstract: Primary biliary cirrhosis (PBC) is a chronic progressive liver disease that often leads 
to fibrosis, cirrhosis, and end-stage liver disease. The diagnosis is made when there is evidence 
of cholestasis and reactivity to the antimitochondrial antibody. The etiology of PBC is poorly 
understood; however, several lines of evidence suggest an environmental factor that triggers a 
series of immune-mediated inflammatory reactions in the bile ducts in a genetically susceptible 
individual. Fatigue and pruritus are the most common symptoms of PBC; however, many patients 
are diagnosed with PBC only based on laboratory abnormalities. The only  pharmacological 
treatment approved for PBC is ursodeoxycholic acid (UDCA). Several controlled studies 
have shown that UDCA improves liver biochemistries and prolongs transplant-free survival in 
PBC patients. Nearly 40% of PBC patients do not respond to UDCA, and those patients are at 
high risk of serious adverse events, such as the development of liver failure. Therefore, newer 
 alternative therapeutic options for PBC are needed. Obeticholic acid is a first-in-class farnesoid 
X receptor agonist that has been recently evaluated in PBC patients with inadequate response 
to UDCA, and demonstrated beneficial results in improving liver biochemistries. Several other 
agents (fibrates and glucocorticoids) have been previously examined in PBC patients with inad-
equate response to UDCA, and preliminary results showed biochemical improvement. However, 
large-scale controlled clinical trials are needed to determine the long-term effects of fibrates 
and glucocorticoids on the clinical outcomes of PBC. Clinical trials of NGM282 (a fibroblast 
growth factor-19 analog) and Abatacept (a fusion protein composed of the Fc  portion of immu-
noglobulin G1 fused to CTLA4) are currently underway.
Keywords: primary biliary cirrhosis, antimitochondrial antibody, farnesoid X receptor, fibrates, 
glucocorticoids
Introduction
Definition and significance of primary biliary cirrhosis
Primary biliary cirrhosis (PBC) is a relatively rare but important cause of liver  disease 
in the Western society. The disease affects ,200,000 individuals in the USA and has 
been designated as an orphan disease by the US Food and Drug Administration.1 
Recent PBC epidemiological studies in North America, Europe, and Australia have 
reported a prevalence of 1.9–40.2 per 100,000 population and an incidence of 0.39–9.8 
per 100,000 population.2 Since it was first described in the year 1851 by Addison and 
Gull,3 significant progress has been made in the diagnosis and management of PBC.
PBC is an autoimmune disease characterized histologically by chronic  inflammation 
and destruction of the interlobular bile ducts and affects women more commonly 
than men (ratio 10:1).4 The sera of nearly 95% of patients with PBC test positive 
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for the antimitochondrial antibody (AMA), and the most 
common biochemical abnormality in PBC is an elevated 
serum  alkaline phosphatase (ALP) level.5 The diagnosis of 
PBC can be made when two of the following criteria are 
met (provided that other causes of intra- and extrahepatic 
cholestasis have been excluded): 1) evidence of cholestasis 
based on serum ALP elevation, 2) the presence of AMA, and 
3)  histological evidence of PBC. These criteria are endorsed 
by the  American Association for the Study of Liver Diseases 
and the European Association for the Study of the Liver.5,6
AMA is an autoantibody found in the majority of patients 
with PBC (∼95%) and targets a family of mitochondrial 
enzymes named the 2-oxo-acid dehydrogenase complexes.7–9 
The levels of AMA may vary through the course of PBC, and 
there seems to be no relationship between the AMA level 
and the degree of severity or stage of PBC.5 Enzyme-linked 
immunosorbent assay, immunoblotting, and indirect immu-
nofluorescence are the most common methods used for AMA 
detection.9 AMA is rarely found in healthy individuals, with 
a reported prevalence rate ranging from 0.5% to 2%.10–13
Presentation of and conditions  
associated with PBC
PBC is often diagnosed in a preclinical asymptomatic 
phase, after screening liver blood tests have been ordered 
by a primary care provider.14 Fatigue15–19 and pruritus20–23 are 
the most frequent symptoms of PBC, present in 60%–80% 
and 20%–70% of patients, respectively, and both have a 
marked negative impact on the quality of life of patients with 
PBC. Other manifestations of PBC include xanthomas and 
 xanthelasmas (from underlying associated hyperlipidemia), 
vitamin D deficiency, osteopenia, and osteoporosis.14 When 
PBC has progressed to stage IV fibrosis (cirrhosis), portal 
hypertension may ensue with hepatomegaly, splenomegaly, 
ascites, varices, hepatic encephalopathy, and jaundice.5 
Fatigue in PBC may lead to inability to work, depression, 
poor quality of life, more aggressive disease, and decreased 
survival.15–17,24–31 Pruritus has been associated with severe 
excoriations, skin bleeding, inability to sleep, and more 
aggressive disease.22,30,32–40 Severe pruritus can be very 
 debilitating and is considered an acceptable indication for 
liver transplantation regardless of Child–Turcotte–Pugh or 
model for end-stage liver disease score by some centers.16,36,41 
PBC is associated with other autoimmune intra- and 
 extrahepatic conditions such as autoimmune hepatitis,42–45 
Sjogren’s  syndrome, arthritis,46 thyroid diseases,  scleroderma, 
Raynaud’s phenomenon, type I diabetes mellitus, systemic 
lupus erythematosus, and celiac disease.47
etiology and pathogenesis of PBC
The cause of PBC remains unidentified. There is increasing 
evidence that PBC is caused by an environmental factor that 
triggers a series of inflammatory reactions in a genetically 
susceptible host, leading to PBC.48,49 Cigarette smoking, 
infections (particularly urinary tract and Helicobacter pylori 
infections), the use of hormone replacement therapies, and 
frequent use of nail polish have been found to be associated 
with an increased risk of PBC.50–53 The strong spatial variation 
of risk and clustering of PBC cases in certain geographical 
areas around the world (around superfund toxic waste sites 
in New York City,54 near the Revelin reservoir in England,55 
the Tyneside region in Northeast England,49 and in Hiroshima 
among the survivors of the atomic bomb56) suggest that one 
or more environmental risk factors are implicated in the 
pathogenesis of PBC, and that toxin exposure may be respon-
sible for the clustering of PBC cases. In PBC, humoral and 
cellular immune responses are exaggerated, likely due to the 
loss of tolerance to self-antigens.57,58 PBC patients frequently 
exhibit high levels of serum autoantibodies (immunoglobulin 
[Ig] M, IgG, and IgA) and significantly increased numbers 
of cytotoxic T (CD8+) and helper T (CD4+) lymphocytes 
compared to control subjects.57–63 Helper T (CD4+) lympho-
cytes release cytokines (such as interleukin [IL]-1, IL-2, 
IL-4, IL-6, interferon-γ) that activate cytotoxic T (CD8+) 
lymphocytes, which in turn directly destroy the hepatocytes 
and cholangiocytes.64–66 In addition, the cytokines released by 
the helper T (CD4+) lymphocytes recruit natural killer cells, 
which contribute to the destruction of biliary epithelium.57,64 
The overexpression of the major histocompatibility complex 
(MHC)-I and MHC-II is believed to contribute to the local 
liver tissue damage that occurs in PBC, as they enable the 
recognition of the self-antigens by the activated lymphocytes, 
leading to further destruction of the portal tracts and sur-
rounding hepatic tissue.57,58
It is strongly believed that accumulation of the toxic 
hydrophobic bile acids in the liver tissue contributes to the 
liver damage that occurs in PBC.67–69 Therefore, modulation 
of the bile acid pool or removal of the toxic hydrophobic bile 
acids would theoretically have beneficial effects in patients 
with PBC. Acting through this mechanism, it is believed that 
ursodeoxycholic acid (UDCA, a naturally occurring hydro-
philic bile acid, and the only agent approved by the US Food 
and Drug Administration for the treatment of PBC) enriches 
the total bile acid pool by replacing the unwanted toxic 
bile acids,70 which can have deleterious effects on the liver 
 tissue. For example, in mice, lithocholic acid has been found 
to promote destruction of the portal tracts and bile ducts.71 
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An Australian group72 monitored 12 patients with PBC 
and six patients with primary sclerosing cholangitis over a 
4-year period. They found that patients with a serum total 
chenodeoxycholic acid (CDCA) concentration at study entry 
that exceeded 15 µmol/L were 10 times more likely to die 
from liver disease or need a liver transplant in the following 
4 years than patients with CDCA levels ,15 µmol/L.
Genetics of PBC
In addition to environmental factors, genetic predisposition 
is believed to play an important role in the development of 
PBC.48 Data from genetics-based studies have shown that 
first-degree family members of PBC patients are at high risk 
of PBC. In one study, the prevalence of PBC has been reported 
to be 720 per 100,000 and 1,200 per 100,000 in first-degree 
relatives and offspring of affected individuals, respectively.73 
In addition, the prevalence of positive AMA (without clinical 
or biochemical evidence of PBC) is high among first-degree 
relatives of PBC patients; one study found that 20% of sisters, 
15% of mothers, and 10% of daughters of PBC patients were 
seropositive for AMA.74 The clinical significance of AMA 
seropositivity in first-degree relatives of PBC patients remains 
unclear. The genome-wide  associated studies have identified 
important gene alleles believed to be related to PBC.73,75–80
Natural history and outcomes of PBC
The progression and outcome of PBC depend on various 
clinical and biochemical factors at the time of diagnosis. 
Asymptomatic PBC patients have a better survival compared 
to patients who have symptoms at the time of diagnosis of 
PBC, and approximately two-third of asymptomatic PBC 
patients develop symptoms over a median time interval of 
4.2–5.3 years of follow-up.81–86 PBC patients have worse 
 survival than the general healthy population, irrespective of 
the presence or absence of symptoms at the time of diagnosis.5 
Risk factors that have been associated with poor prognosis 
of PBC are male sex, the presence of symptoms at diagnosis 
of PBC, elevated serum bilirubin, elevated serum ALP, the 
presence of anti-Sp100 and anti-gp210  autoantibodies, pro-
longed prothrombin time, development of esophageal varices, 
inadequate response to UDCA, and advanced histological 
stage.83,87–94 Despite its rarity, PBC remains an important 
cause of morbidity in the Western world. Many patients 
with PBC progress to cirrhosis and end-stage liver disease, 
requiring liver transplantation.95 PBC is one of the leading 
indications for liver transplantation.41,95,96 Moreover, PBC has 
been identified as an important risk factor for hepatocellular 
carcinoma.93,97–102
Current pharmacological  
treatment of PBC
UDCA is the only drug approved by the US Food and 
Drug Administration for the treatment of PBC. Several 
controlled and uncontrolled clinical trials have shown that 
UDCA improves liver biochemistries, delays histological 
progression, delays development of esophageal varices, 
and improves the transplant-free survival in patients with 
PBC.103–111 UDCA is 3α,7β-dihydroxy-5β-cholanoic acid, a 
bile acid with two hydroxy groups (–OH) at positions 3 and 
7 in the cholane ring structure, with an α- and β-orientation, 
respectively.112 The C-7 β-orientation confers the molecule 
a far higher hydrophilicity than that of its structural analog 
with an α-orientation, CDCA.112
The exact mechanism of action of UDCA in PBC has 
not been established yet. However, there are a number 
of proposed mechanisms by which UDCA is thought to 
exert its beneficial effects in PBC. First, UDCA changes 
the  hydrophobicity index of the endogenous bile acid pool 
and replaces the potentially toxic hydrophobic bile acids 
by enriching the endogenous bile acid pool.70,112 UDCA 
 comprises no more than 4% of the total endogenous bile 
acid pool in healthy individuals, whereas this percentage is 
increased to 40%–60% in individuals taking conventional 
UDCA doses of 13–15 mg/kg body weight per day.113 
Depending on the dose used, UDCA enriches the bile acid 
pool, accounting for 19%–64% of the total biliary bile 
acids.114 These effects are thought to protect the liver tissue 
against the deleterious effects of detergent bile acids. Second, 
UDCA protects hepatocytes and cholangiocytes against cell 
death induced by the cytotoxic bile acids by counteracting 
the extrinsic and intrinsic apoptotic pathways responsible for 
the hepatocyte and cholangiocyte damage in PBC.112 Third, 
UDCA decreases the intracellular concentration of bile 
acids and favors their elimination through the urinary route 
by preventing the uptake of bile acids by hepatocytes (by 
downregulating the organic anion-transporting  polypeptide 1, 
a basolateral transporter involved in bile acid hepatocyte 
uptake),115 enhancing the excretion of conjugated bile 
acids into the blood (by upregulating the basolateral export 
pumps multidrug resistance-associated protein [Mrp] 3 and 
Mrp4),116–118 repressing bile acid synthesis,119 and eliminating 
the toxic bile acids through the kidneys (by upregulating the 
renal apical bile acid export pumps Mrp2 and Mrp4).116,120–122 
Fourth, UDCA reduces portal inflammation and ductular 
proliferation and preserves bile duct integrity by  stimulating 
HCO
3
– secretion by the cholangiocytes.123–125 HCO
3
–  secretion 
is thought to improve the bile flow through the affected 
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bile ducts, thus ameliorating the deleterious effects of 
toxic bile acids on the liver tissue.126 Fifth, UDCA exerts 
 immunomodulatory and anti-inflammatory effects on the 
humoral and cellular immune responses by suppressing the 
production of autoantibodies,127 suppressing the cytotoxic 
T (CD8+) and helper T (CD4+) lymphocytes,127,128 inhibiting 
the release of cytokines produced by immune cells (IL-2, 
IL-4, interferon-γ, and tumor necrosis factor-α),127,129–132 and 
inhibiting the overexpression of cell surface molecules such 
as MHC-I, MHC-II, intercellular adhesion molecule-1, and 
lymphocyte function-associated antigen-1.133–135
Progress in the treatment of PBC
Despite the proven efficacy of UDCA in PBC, nearly 40% 
of PBC patients do not respond adequately to  treatment 
with UDCA.136 There are several criteria proposed to define 
 biochemical response and nonresponse to UDCA ther-
apy:89,136–140 the Mayo Clinic criteria137 (serum ALP decrease 
to ,2 times the upper limit of normal [ULN] at 6 months 
of UDCA  treatment), Barcelona criteria136 (serum ALP 
decrease to .40% from baseline or to normal value after 
12 months of UDCA treatment), Paris  criteria89 (decrease in 
serum ALP to #3 times ULN, decrease in serum  aspartate 
 aminotransferase to #2 times ULN, and normal serum 
bilirubin after 12 months of UDCA  treatment), Toronto 
criteria141 (decrease in serum ALP to #1.67 times ULN after 
12 months of UDCA  treatment), and the  Rotterdam crite-
ria139 ( normalization of serum bilirubin and  albumin after 
12 months of UDCA treatment when one or both parameters 
were abnormal before treatment, or normalization of serum 
bilirubin or albumin after 12 months of UDCA treatment 
when both were abnormal before  treatment). These criteria of 
biochemical response to UDCA have now become  surrogate 
markers of  therapeutic efficacy in PBC. PBC patients who 
have  suboptimal  biochemical response to UDCA  treatment 
are at risk of late and  serious  complications, such as 
 development of liver cirrhosis,  hepatocellular carcinoma, 
and signs of portal hypertension,14 and therefore, newer 
treatments for PBC are needed, as discussed later.
Farnesoid X receptor agonists and PBC
Farnesoid X receptors (FXRs)142 are nuclear hormone 
 receptors expressed in high quantities in tissues that are 
involved in bile acid, carbohydrate, and lipid metabolism, 
such as the liver and intestines.143 Manipulation of FXR 
is a breakthrough that has significantly improved our 
 understanding of bile acid metabolism, and it also opened 
new therapeutic avenues for many liver disorders such 
as nonalcoholic fatty liver disease and cholestatic liver 
diseases.
Rationale for use
FXRs have been found to be important, key regulators of 
bile acid metabolism in humans.143 When activated, FXR 
 modulates the bile acid size and pool composition by reducing 
the production of endogenous bile acids through suppression 
of the gene encoding the enzyme cholesterol 7α-hydroxylase, 
the rate-limiting step in the biosynthesis of endogenous bile 
acids.144 The reduction of the total bile acid pool decreases 
the bile acid workload on the liver, with beneficial effects 
on liver health and regeneration capacity.145 Bile acids have 
been found to be natural ligands of FXR.144 In addition to 
directly suppressing the gene encoding the enzyme cho-
lesterol 7α-hydroxylase, FXR activation has been found 
to indirectly suppress cholesterol 7α-hydroxylase through 
regulating the expression of an intestinal growth factor 
named fibroblast growth factor-19 (FGF-19).146,147 FGF-19 
has been found to suppress the expression of cholesterol 
7α-hydroxylase in human hepatocytes through a c-Jun 
N-terminal kinase-dependent pathway.148 FXR also plays 
a key role in the enterohepatic circulation, as activation of 
FXR results in expression of the cytosolic intestinal bile 
acid-binding protein.149 This protein facilitates the movement 
of bile acids from the intestines through the enterocytes into 
the portal circulation.150
Preclinical experiments have shown that FXR activation 
protects against bile acid-related injury to the liver, prevents 
development of liver fibrosis, and exerts immunoregula-
tory effects on cells of innate immunity.151,152 Collectively, 
these effects could be of therapeutic benefit to patients with 
cholestatic liver diseases. Obeticholic acid (OCA), also 
known as INT-747, is a first-in-class selective FXR agonist. 
It is a 6α-ethyl derivative of CDCA and selectively binds to 
FXR, with ∼100-fold greater binding affinity to FXR than 
to CDCA.152
Clinical experience
OCA has been recently investigated in 165 patients with PBC 
who had an inadequate response to UDCA.153 In this Phase II 
clinical trial, patients with PBC and inadequate response to 
UDCA were initially randomized to either placebo or one of 
the three OCA treatment groups (10 mg, 25 mg, and 50 mg per 
day) for 3 months. All patients  continued UDCA  treatment 
on a stable dose throughout the study period. After comple-
tion of the initial 3 months of  treatment (the randomized 
 placebo-controlled phase), 78 patients  continued  treatment 
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with OCA in an open-label extension clinical trial for 
12 more months.153 The primary endpoint was the  percentage 
change in serum ALP from baseline value (on day 0) to 
the end of  treatment in the randomized  placebo-controlled 
phase (day 85). Patients in the OCA treatment groups expe-
rienced significant  reductions in serum ALP, γ-glutamyl 
transpeptidase (GGTP), alanine aminotransferase, aspartate 
 aminotransferase, and  bilirubin levels,  compared to patients 
in the placebo group.153  Specifically, mean serum ALP 
reduced from baseline values by 24%, 25%, and 21% in the 
OCA 10 mg, OCA 25 mg, and OCA 50 mg per day groups, 
respectively, compared to only a 3% reduction in serum 
ALP in the placebo group.  Statistically significant change 
in serum ALP values in the OCA groups was observed as 
early as 2 weeks of treatment.153 Only 7% (7/99) of patients 
in the OCA groups experienced  normalization of serum ALP 
compared to none in the  placebo group. Pruritus was the 
principal side effect in the OCA treatment groups: 92/127 
(72.4%) compared to 19/38 (50%) in the placebo group.153 
The incidence and severity of pruritus were worse in the 
intermediate- and high-dose OCA treatment groups. The 
incidence of pruritus in the open-label extension trial phase 
was 87% (68/78), and 13% (10/78) discontinued OCA due 
to severe pruritus. Patients who were enrolled in the open-
label extension clinical trial maintained biochemical response 
throughout the 12-month treatment period.
Patients in the OCA treatment groups (low,  intermediate, 
and high dose) experienced significant reductions in serum 
ALP by the end of treatment, and this is important because 
ALP is a prognostic marker in PBC patients. In a recent 
meta-analysis involving 4,845 PBC patients from 15 North 
American and European clinical centers,87 ALP was a strong 
predictor of clinical outcomes (liver transplantation or death), 
and PBC patients who experienced ALP reduction had bet-
ter survival than those who had persistently elevated serum 
ALP levels.87 Although the mean serum bilirubin levels were 
normal for patients enrolled in this study, PBC patients in 
the intermediate-dose and high-dose OCA treatment groups 
experienced statistically significant reductions in their serum 
bilirubin by the end of treatment. This is another potentially 
important finding, because elevated bilirubin is the strongest 
predictor of clinical outcomes and survival in patients with 
PBC.154 Mean serum ALP levels continued to further decrease 
in the group of patients who were enrolled in the open-
label extension trial phase (285±15 U/L at baseline versus 
210±12 U/L at 3 months versus 202±11 U/L at 12 months 
of OCA treatment), suggesting that OCA treatment in 
patients with PBC should be continued for at least 1 year, if 
not indefinitely, to observe the desired effect of OCA on the 
long-term outcomes of PBC.
There are several questions that remain to be answered: 
1) What is the effect of the combination therapy of OCA 
and UDCA on the clinical course and long-term outcomes 
of PBC? 2) What are the long-term side effects and adverse 
events related to OCA alone, and to the combination therapy 
of OCA and UDCA, if any? 3) What is the effect of OCA 
monotherapy on short- and long-term outcomes in PBC 
patients? Clearly, to answer these questions, large-scale and 
long-term controlled clinical trials are needed.
Fibrates and PBC
Fibrates (fenofibrate and bezafibrate) are fibric acid deriva-
tives that are widely used for the treatment of  hyperlipidemia 
and hypertriglyceridemia. Fibrates act mainly by  suppressing 
acetyl coenzyme A carboxylase.155 The peroxisome 
 proliferator-activated receptors (PPARs) are the main 
molecular  targets of fibrates.156 There are three distinct 
isoforms of PPARs in humans that are encoded by distinct 
genes: PPAR-α, PPAR-δ, and PPAR-γ.157 PPAR-α is highly 
expressed in tissues that participate in lipid metabolism, such 
as the liver, kidney, heart, and skeletal muscle, and activation 
of PPAR-α results in β-oxidative degradation of fatty acids 
and regulation of transcription of genes involved in lipid 
metabolism.158,159 Fibrates exhibit different potencies to all 
three human isoforms of PPARs.157
Rationale for use
In 1999, Iwasaki et al noted that patients with hypercholes-
terolemia experienced significant reductions in serum ALP, 
GGTP, and IgM when they were started on bezafibrate.160 
Based on these events, they suggested that treatment with 
fibrates might be of therapeutic benefit in patients  suffering 
from cholestatic liver disease. Since then, significant bio-
chemical improvement in patients with PBC receiving 
fibrates (bezafibrate and fenofibrate) has been reported 
across several pilot studies, and Phase III clinical trials are 
needed.161
Although the exact mechanism of action of fibrates 
in cholestatic liver diseases remains unclear, several 
hypotheses have been proposed. PPAR-α activation results 
in downregulation of bile acid synthesis by inhibiting 
cholesterol 7α-hydroxylase and sterol 27-hydroxylase162 
and  regulation of bile acid detoxification by upregulation 
of uridine 5′-diphospho-glucuronosyltransferase 2B4, 
cytochrome P450 3A4, apical sodium-dependent bile acid 
transporter (ASBT), and sulfotransferase 2A1.159,163–165 
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These induced changes in bile acid metabolism are 
thought to be beneficial in patients with cholestatic liver 
diseases. Fibrates have been found to directly enhance 
biliary  excretion of phosphatidylcholine by upregula-
tion of the Mrp3 through stimulation of PPAR-α.166 
This activity is thought to be important because it aids 
in the excretion of the toxic hydrophobic bile acids by 
forming hydrophilic compounds and micelles. In animal 
models, fibrates  minimize the degree of injury induced 
by cholestasis by upregulation of the Mrp4 and Mrp3.167 
These proteins are normally expressed in the basolateral 
surfaces of the  hepatocytes and play a crucial role in the 
efflux of bile acids into the systemic circulation.168 In 
cholestasis, their upregulation is therapeutically impor-
tant because it is believed to be a defensive mechanism 
by which the liver minimizes the tissue damage caused 
by cholestasis.169
Nitric oxide (NO) production pathway is an attractive 
therapeutic target in many diseases. NO production is 
 catalyzed by the enzyme nitric oxidase synthase.170 In inflam-
matory and autoimmune states, NO contributes to the tissue 
inflammation by damaging the mitochondria and inducing 
proinflammatory cytokines.170 Increased levels of NO in the 
sera and increased expression of nitric oxidase synthase at 
the site of damaged biliary epithelial cells have been reported 
in PBC.171–173 It has been proposed that fibrates ameliorate 
portal tract inflammation and bile duct injury in PBC by 
downregulation of NO production.174
Fibrates have also been found to inhibit migration of 
immune cells to the liver in PBC by decreasing the  expression 
of bile acid-induced regulated upon activation normal 
T-cell expressed and secreted (RANTES) and by inhibiting 
DNA-binding activity and transcriptional activity of nuclear 
factor kappa B (NF-κB).175 In addition, fibrates may also 
have immunoregulatory effects in PBC such as inhibiting 
CD4+CD25+ regulatory T-cells (Tregs) apoptosis induced 
by B-cell  activating factor.176 Tregs play a critical role in 
controlling the production of inflammatory cytokines by 
the activated immune cells in autoimmune conditions such 
as PBC.176
In patients with PBC, the addition of bezafibrate to 
UDCA improved the serum hepatic fibrosis parameters,177 
suggesting that fibrates not only act as inflammatory agents 
in PBC but also act as antifibrotic agents. A recent study 
has shown that fibrates act as both PPAR-α and pregnane X 
receptor (PXR) agonists.178 Collectively, these data suggest 
that fibrates might be of therapeutic benefit in patients with 
cholestatic liver diseases.
Clinical experience
Several pilot studies have consistently shown that fibrates 
might be of therapeutic benefits in patients with cholestatic 
liver diseases, particularly PBC.160,179–192 The use of fibrates 
in PBC has demonstrated satisfactory outcomes with an 
excellent safety profile, and although results are preliminary, 
data suggest that fibrates are beneficial in PBC. However, 
large-scale multicenter clinical trials are awaited. Most of 
the studies reported the use of fibrates in addition to UDCA 
in PBC patients with insufficient response to UDCA, and 
fibrates are not approved by the federal health agencies for 
the treatment of PBC. Only one pilot study reported the use 
of bezafibrate alone compared to UDCA in PBC patients.182 
In this clinical trial, patients in the bezafibrate group showed 
more signif icant improvement in liver biochemistries 
 compared to patients in the UDCA group.182
Fibrate use results in significant reduction in cholestatic 
parameters (serum ALP and GGTP), transaminases, and 
IgM levels in PBC.160,179,182–184,189–192 Effects of fibrates on 
the biochemical parameters can be observed as early as 
1 month of the beginning of therapy, and most patients 
sustained the biochemical response as long as they were 
on fibrates.  Discontinuation of fibrates results in rebound 
elevation of biochemical indices in patients with PBC, and 
an  improvement in the biochemical indices is almost always 
observed after treatment with fibrates is reinstituted, further 
supporting the potential therapeutic benefit in PBC. The 
effects of fibrates on the histological progression of PBC 
have been reported from only two studies; one study showed 
amelioration of portal tract inflammation and cholangitis in 
two out of three cases of PBC,187 and another study showed 
no significant change in follow-up histological evaluation 
in one case and histological progression in the other case 
of PBC.181
Almost all studies have shown a remarkable reduction 
in serum IgM when measured, and whether this change is 
of prognostic importance in PBC patients receiving fibrates 
is unclear. In addition to the biochemical improvement, 
significant pruritus relief has been observed in patients with 
PBC with inadequate response to UDCA following institu-
tion of fibrate therapy.183 Patients experienced worsening 
of pruritus when bezafibrate was discontinued, and pruritus 
improved or completely disappeared after bezafibrate was 
reinstituted.183 These data lend support to the use of fibrates 
in PBC patients, and suggest that fibrates could be used in 
the management of pruritus.
Data from a preliminary Spanish study examining the 
effects of bezafibrate on symptoms and hepatic biochemical 
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indices in PBC patients with inadequate response to UDCA 
suggest that patients with early-stage PBC benefit more from 
the combination therapy than patients with advanced-stage 
PBC.183 These results need to be verified in a large-scale, 
long-term clinical trial.
The use of fibrates in PBC patients (alone or in combina-
tion with UDCA) has been shown to be generally safe and 
well tolerated. Heartburn and nausea are the most commonly 
reported side effects related to fibrates therapy in PBC, with 
a reported incidence of 25% and 15%, respectively.190 In 
the pilot study reported from the US, one out of 20 PBC 
patients developed ulcerative esophagitis, possibly related to 
 treatment with fenofibrate.190 Elevated serum transaminases 
(2–5 times the ULN) have been reported (∼10%), but these 
events are usually transient, lasting a few weeks, and rarely 
lead to discontinuation of the drug.190
The long-term use (∼9 years) of combination therapy 
of UDCA and bezafibrate in PBC patients with inadequate 
response to UDCA has been associated with increased serum 
creatinine levels,193 raising concerns for potential kidney 
injury due to fibrates. Although these studies have provided 
useful preliminary information with regard to the use of 
fibrates in PBC, they are criticized for small sample sizes, 
short-term duration of therapy, scarcity of data collected, and 
more importantly, lack of control groups.
Glucocorticoids and PBC
Glucocorticoids (GCs) have long been used in the  treatment of 
numerous inflammatory and autoimmune clinical  conditions 
such as asthma, Crohn’s disease, and  autoimmune  hepatitis. 
In this review, we discuss the role of GCs,  particularly 
 budesonide, in the treatment of PBC.
Rationale for use
GCs are known to suppress the inflammation by various 
ways. GCs act mainly via a cytosolic GC receptor (cGCR) 
that binds to specific DNA-binding sites resulting in induced 
synthesis of anti-inflammatory molecules such as lipocortin 
1 and IκB, and suppression of transcription of  inflammatory 
genes such as IL-1, IL-2, tumor necrosis factor-α, and 
interferon-γ.194 Moreover, the GC/cGCR complex  interacts 
physically with NF-κB to block its transcriptional  activity 
within the cell.195 NF-κB carries out key functions in 
the induction and  perpetuation of inflammation such as 
 stimulation of transcription of chemokines, inflammatory 
cytokines, complement proteins, cell adhesion molecules, 
and receptors for these molecules.196 NF-κB also induces 
transcription of cyclooxygenase 2, an enzyme essential for 
prostaglandin production.196 GCs suppress the dendritic cell 
activity, decrease the number of B-cells, attenuate B-cell 
progenitor proliferation, and  suppress antibody  production 
by B-cells.194 GCs inhibit helper and cytotoxic T-cell  activity, 
and suppress production of cytokines by T-cells.194 More 
recently, GCs have been found to improve bile flow in 
cholestatic conditions by upregulation of the anion exchanger 
2 protein,197 which may play an important role in biliary 
excretion of bicarbonate.
Clinical experience
GCs have been evaluated in patients with PBC.  Prednisolone 
use in PBC improves liver biochemistries, but its  extensive 
systemic side effects hamper its long-term use.198,199 
Budesonide has gained more attention recently due to its 
high binding affinity to GC receptors and relatively low 
bioavailability.200
Two randomized clinical trials have shown that the 
combination therapy of UDCA and budesonide was 
superior to UDCA alone in PBC.201,202 In particular, the 
 combination therapy of UDCA and budesonide improved 
liver  biochemistries and histological abnormalities compared 
to UDCA alone.201,202 The reduction in liver chemistries was 
significantly more pronounced in the combination therapy 
(UDCA plus budesonide) groups.201,202 Side effects reported 
were acne, skin bruises, hirsutism, nausea, and weight 
gain.201,202
In a German study,201 the reported changes in the bone 
mineral density (BMD) after 2 years of treatment were not 
significant between the two treatment groups (-1.74% in 
the UDCA plus budesonide group versus -0.98% in the 
UDCA monotherapy group). In the Finnish study,202 the 
reported change in BMD after 3 years of treatment was not 
significant between the two groups (UDCA plus budesonide 
versus UDCA alone). In the UDCA plus budesonide group, 
the BMD in femoral neck and lumbar spine was decreased 
by 3.6% and 2.8%, respectively, from the baseline.203 In the 
UDCA monotherapy group, the corresponding decreases 
were 1.9% and 0.7% from baseline.203
In a 1 year open-label study204 of 22 PBC patients with 
inadequate response to UDCA, the addition of budesonide 
resulted in marginal improvement of serum ALP and 
 bilirubin. In this study, treatment with the combination 
therapy was associated with significant bone loss in the 
lumbar spine.204 This study204 included a small number of 
patients (n=22) compared to the German (n=40)201 and 
 Finnish (n=69)202 clinical trials, and had no comparator group. 
These data suggest that combination therapy of UDCA and 
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budesonide is potentially safe and effective in patients with 
early-stage PBC, and long-term clinical trials are warranted. 
BMD should be regularly monitored in PBC patients on 
budesonide therapy.201–204 The use of budesonide in patients 
with advanced-stage PBC, however, has been associated with 
serious adverse events (mainly portal vein thrombosis).205
Combination therapy with UDCA (13–15 mg/kg body 
weight per day), budesonide (6 mg per day), and mycophe-
nolate mofetil (MMF, 1 g per day) has been shown in a pilot 
study to improve the liver biochemistries and histological 
abnormalities in 13 out of 15 patients with non-cirrhotic 
PBC with significant interface hepatitis who had suboptimal 
response to UDCA alone.206 Taken together, these studies 
suggest that the UDCA–budesonide combination therapy, 
with or without MMF, could be considered in PBC patients 
with suboptimal response to UDCA alone. Patients with 
pre-cirrhotic-stage PBC are more likely to benefit from 
GC therapy than patients with cirrhotic-stage PBC.199 The 
UDCA–budesonide combination therapy is currently being 
evaluated in a randomized clinical trial in Europe.
Other treatments in PBC
NGM282 is an FGF-19 analog and downregulates bile 
acid synthesis by decreasing the expression of cholesterol 
7α-hydroxylase. NGM282 is currently being investigated 
in a Phase II clinical trial in patients with PBC.
The CD28/CTLA4:B7 costimulatory pathway is a crucial 
step in T-cell-dependent B-cell activation and is characterized 
by binding of CD28 and CTLA4 on T-cells to B7-1 and B7-2 
on activated antigen-presenting cells (B-cells, macrophages, 
and dendritic cells).207 Binding of CD28 to B7-1 and B7-2 
results in T-cell activation, proliferation, differentiation, 
and release of inflammatory cytokines.207 On the other 
hand,  binding of CTLA4 to B7-1 and B7-2 results in inhibi-
tion of T-cell activation, proliferation, and differentiation. 
Abatacept,207 a fusion protein composed of the Fc portion 
of IgG1 fused to CTLA4, is currently being investigated in 
PBC patients with inadequate response to UDCA.
The ASBT (or SLC10A2), localized at the apical  membrane 
of the cholangiocytes, ileum, and renal  proximal tubules, 
plays an important role in maintaining the  enterohepatic 
circulation of bile salts.208 Uptake of bile salts across the 
apical membrane of enterocytes is mediated by the ASBT.208 
Inhibition of ASBT results in disruption of the enterohepatic 
circulation and increased fecal loss of bile salts.209 The 
resultant inhibition of uptake of bile salts at the intestinal 
level reduces the amount of bile salts circulating back to the 
liver, and this effect is thought to be of therapeutic benefit in 
patients suffering from cholestatic liver diseases. LUM001, 
a novel ASBT inhibitor, is currently being  evaluated in a 
Phase II clinical trial in patients with PBC.
The TGR5 receptor, the first known G-protein-coupled 
receptor specific for bile acids,210 is distributed throughout 
the body organs and tissues, including the liver, and is 
found in Kupffer cells, liver sinusoidal endothelial cells, 
biliary tree, and gall bladder epithelial cells.211 Experimental 
studies have shown that TGR5 receptor activation results 
in downregulation of inflammatory responses, and212,213 
stimulation of NO production,214 and bicarbonate secretion 
by the biliary epithelium.215 These physiological effects 
might have important therapeutic implications in hepatic 
diseases, including PBC. Several TGR5 receptor agonists 
are currently being developed. Clinical trials are needed 
to examine whether TGR5 receptor agonists have clinical 
efficacy in the  treatment of PBC.
The nuclear receptors, constitutive androstane  receptor 
(CAR) and PXR, participate in the regulation of genes 
involved in the detoxification and transportation of bile acids 
and bilirubin.216 Preclinical studies have shown that activation 
of CAR and PXR through ligands increases the expression 
of hepatic export systems (Mrp2, Mrp3, and Mrp4) for bile 
acids and bilirubin, enhances the detoxification of biliary 
compounds, and reduces serum levels of bilirubin and bile 
acids.217 The hepatic expression of the Mrp2 and Mrp3 has 
been shown to be enhanced only in the early stages of PBC 
compared to the late stages of PBC, suggesting that the lack of 
upregulation of these proteins contributes to the progression 
of PBC.218 Clearly, clinical trials are needed to test the role 
of CAR and PXR agonists in the treatment of PBC.
Nor-UDCA, a novel C23 homolog of UDCA, has been 
shown to have potent choleretic and antifibrotic effects in 
mouse models of liver disease.219–222 These findings might 
be of therapeutic significance in PBC. Currently, a clinical 
trial of nor-UDCA in primary sclerosing cholangitis patients 
is underway.
Challenges in the treatment of PBC
There are several challenges in the development and evalua-
tion of new treatments for PBC. First, PBC is an uncommon 
disease and is designated as an orphan disease by the US Food 
and Drug Administration. The relative rarity of PBC does 
not easily allow enrollment of the number of study subjects 
needed to detect a statistically significant difference when 
comparing a candidate agent against a comparator (such 
as placebo). Consequently, the results of clinical trials are 
frequently based on a small group of patients, and strong 
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conclusions regarding preliminary safety and efficacy data 
are often difficult to make. Even Phase III clinical trials in 
PBC are often criticized by the small number of patients 
enrolled for the study. For example, the Canadian multicenter 
randomized clinical trial,106 one of the largest trials to date in 
PBC, enrolled only 54.4% (222/408) of the planned number 
of study subjects.
PBC is a chronic liver disease with a variable course that 
often slowly progresses to fibrosis, cirrhosis, and end-stage 
liver disease. Natural history studies of PBC have shown that 
the estimated median survival of PBC is 10–15 years.83,86 In 
reality, PBC patients enrolled in clinical trials of  candidate 
agents should be followed for at least 10 years (after an 
 enrollment period of ∼3–5 years) to determine the true 
effect of the new candidate agent on the clinical outcomes 
of the disease. This is impractical because of the difficulty 
in  enrolling the required number of patients in a short period 
of time and the difficulty in retaining the study subjects for 
such a long period of time.223,224
Another major challenge in developing an effective 
 treatment for PBC is the lack of surrogate endpoints.225 There 
has been an intense search to identify accurate noninvasive 
markers that could serve as surrogate endpoints in clinical 
trials of PBC.87 For a surrogate endpoint to be an effective 
substitute for the clinical outcome of a specific disease or 
condition, the effects of the intervention (drug, biological 
agent, device, procedure, etc) on the surrogate endpoint 
must reliably predict the overall effect on the clinical 
 outcome.226 Generally, surrogate endpoints can be useful in 
Phase II  clinical trials for identifying if a new intervention 
is  promising enough to be evaluated in a Phase III clinical 
trial.226 In Phase III clinical trials, the endpoint ideally should 
be a clinical event relevant to the patient.226 In PBC, of all 
the noninvasive markers, serum bilirubin is the strongest 
predictor of clinical outcome.92,154 Serum bilirubin levels in 
PBC patients tend to increase as the disease  progresses.227 
Thus, one might expect a favorable outcome if a new 
 treatment results in a decrease in serum bilirubin level to 
the normal range and maintenance of serum bilirubin level 
within the normal range over a long period of time. In PBC, 
serum bilirubin levels tend to increase in the late  stages.227 
Therefore, serum bilirubin could serve as a surrogate end-
point only in patients with advanced-stage PBC. ALP as 
discussed previously is currently the most frequently used 
surrogate measure in clinical trials in PBC. The use of liver 
stiffness measurements (measured by transient elastography, 
TE) as a surrogate endpoint in clinical trials of PBC has 
been recently evaluated. TE has been shown to have high 
performance (diagnostic performance of 0.92 for fibrosis 
stage $3, and 0.99 for fibrosis stage =4)228 and to perform 
better than noninvasive markers228 in identifying any grade 
of fibrosis or cirrhosis in PBC.228–230 Long-term studies are 
needed for confirmation.
Conclusion
PBC is an autoimmune disease of the liver that results in 
destruction of the interlobular hepatic bile ducts.  Currently, 
UDCA is the only drug approved for the treatment of 
PBC. UDCA improves the liver biochemistries, delays 
histological progression, and prolongs survival free of liver 
 transplantation. Approximately 40% of PBC patients do 
not respond to UDCA; these patients are at high risk of 
serious adverse events. There are several new drugs that 
are currently being investigated as alternative therapeutic 
options in patients with PBC who fail UDCA therapy, and 
preliminary results from these clinical trials are promising. 
OCA is a first-in-class FXR agonist that showed encouraging 
results in a Phase III clinical trial in PBC patients who had 
inadequate response to UDCA. Larger controlled clinical tri-
als are needed to determine the long-term effects of fibrates 
and GCs on the clinical outcomes of PBC. Studies to identify 
reliable  surrogate endpoints are needed.
Disclosure
Dr Keith D Lindor is an unpaid advisor for Lumena and 
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